Skip to main content
Erschienen in: Inflammation Research 7/2011

01.07.2011 | Original Research Paper

Comparative analysis of inactivated-state block of N-type (Cav2.2) calcium channels

verfasst von: Timothy A. Vortherms, Andrew M. Swensen, Wende Niforatos, James T. Limberis, Torben R. Neelands, Richard S. Janis, Rama Thimmapaya, Diana L. Donnelly-Roberts, Marian T. Namovic, Di Zhang, C. Brent Putman, Ruth L. Martin, Carol S. Surowy, Michael F. Jarvis, Victoria E. Scott

Erschienen in: Inflammation Research | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to compare a diverse set of peptide and small-molecule calcium channel blockers for inactivated-state block of native and recombinant N-type calcium channels using fluorescence-based and automated patch-clamp electrophysiology assays.

Methods

The pharmacology of calcium channel blockers was determined at N-type channels in IMR-32 cells and in HEK cells overexpressing the inward rectifying K+ channel Kir2.1. N-type channels were opened by increasing extracellular KCl. In the Kir2.1/N-type cell line the membrane potential could be modulated by adjusting the extracellular KCl, allowing determination of resting and inactivated-state block of N-type calcium channels. The potency and degree of state-dependent inhibition of these blockers were also determined by automated patch-clamp electrophysiology.

Results

N-type-mediated calcium influx in IMR-32 cells was determined for a panel of blockers with IC50 values of 0.001–7 μM and this positively correlated with inactivated-state block of recombinant channels measured using electrophysiology. The potency of several compounds was markedly weaker in the state-dependent fluorescence-based assay compared to the electrophysiology assay, although the degree of state-dependent blockade was comparable.

Conclusions

The present data demonstrate that fluorescence-based assays are suitable for assessing the ability of blockers to selectively interact with the inactivated state of the N-type channel.
Literatur
1.
Zurück zum Zitat Catterall WA, Scheuer T, Thomsen W, Rossie S. Structure and modulation of voltage-gated ion channels. Ann N Y Acad Sci. 1991;625:174–80.PubMedCrossRef Catterall WA, Scheuer T, Thomsen W, Rossie S. Structure and modulation of voltage-gated ion channels. Ann N Y Acad Sci. 1991;625:174–80.PubMedCrossRef
2.
Zurück zum Zitat Bao J, Li JJ, Perl ER. Differences in Ca2+ channels governing generation of miniature and evoked excitatory synaptic currents in spinal laminae I and II. J Neurosci. 1998;18:8740–50.PubMed Bao J, Li JJ, Perl ER. Differences in Ca2+ channels governing generation of miniature and evoked excitatory synaptic currents in spinal laminae I and II. J Neurosci. 1998;18:8740–50.PubMed
3.
Zurück zum Zitat Heinke B, Balzer E, Sandkuhler J. Pre- and postsynaptic contributions of voltage-dependent Ca2+ channels to nociceptive transmission in rat spinal lamina I neurons. Eur J Neurosci. 2004;19:103–11.PubMedCrossRef Heinke B, Balzer E, Sandkuhler J. Pre- and postsynaptic contributions of voltage-dependent Ca2+ channels to nociceptive transmission in rat spinal lamina I neurons. Eur J Neurosci. 2004;19:103–11.PubMedCrossRef
4.
Zurück zum Zitat Urban MO, Ren K, Sablad M, Park KT. Medullary N-type and P/Q-type calcium channels contribute to neuropathy-induced allodynia. Neuroreport. 2005;16:563–6.PubMedCrossRef Urban MO, Ren K, Sablad M, Park KT. Medullary N-type and P/Q-type calcium channels contribute to neuropathy-induced allodynia. Neuroreport. 2005;16:563–6.PubMedCrossRef
5.
Zurück zum Zitat Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, Orendacova J, et al. Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp Brain Res. 2002;147:456–63.PubMedCrossRef Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, Orendacova J, et al. Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp Brain Res. 2002;147:456–63.PubMedCrossRef
6.
Zurück zum Zitat Westenbroek RE, Hoskins L, Catterall WA. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci. 1998;18:6319–30.PubMed Westenbroek RE, Hoskins L, Catterall WA. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci. 1998;18:6319–30.PubMed
7.
Zurück zum Zitat Yokoyama K, Kurihara T, Makita K, Tanabe T. Plastic change of N-type Ca channel expression after preconditioning is responsible for prostaglandin E2-induced long-lasting allodynia. Anesthesiology. 2003;99:1364–70.PubMedCrossRef Yokoyama K, Kurihara T, Makita K, Tanabe T. Plastic change of N-type Ca channel expression after preconditioning is responsible for prostaglandin E2-induced long-lasting allodynia. Anesthesiology. 2003;99:1364–70.PubMedCrossRef
8.
Zurück zum Zitat Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001;21:1868–75.PubMed Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001;21:1868–75.PubMed
9.
Zurück zum Zitat Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res. 2001;95:1–8.PubMedCrossRef Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res. 2001;95:1–8.PubMedCrossRef
10.
Zurück zum Zitat Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004;11:3029–40.PubMed Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004;11:3029–40.PubMed
11.
Zurück zum Zitat Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain. 1995;60:83–90.PubMedCrossRef Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain. 1995;60:83–90.PubMedCrossRef
12.
Zurück zum Zitat Saegusa H, Kurihara T, Zong S, Kazuno A, Matsuda Y, Nonaka T, et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J. 2001;20:2349–56.PubMedCrossRef Saegusa H, Kurihara T, Zong S, Kazuno A, Matsuda Y, Nonaka T, et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J. 2001;20:2349–56.PubMedCrossRef
13.
Zurück zum Zitat Kim C, Jun K, Lee T, Kim SS, McEnery MW, Chin H, et al. Altered nociceptive response in mice deficient in the alpha(1B) subunit of the voltage-dependent calcium channel. Mol Cell Neurosci. 2001;18:235–45.PubMedCrossRef Kim C, Jun K, Lee T, Kim SS, McEnery MW, Chin H, et al. Altered nociceptive response in mice deficient in the alpha(1B) subunit of the voltage-dependent calcium channel. Mol Cell Neurosci. 2001;18:235–45.PubMedCrossRef
14.
Zurück zum Zitat Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, et al. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther. 2010;334:545–55.PubMedCrossRef Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, et al. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther. 2010;334:545–55.PubMedCrossRef
15.
Zurück zum Zitat Feng ZP, Doering CJ, Winkfein RJ, Beedle AM, Spafford JD, Zamponi GW. Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. J Biol Chem. 2003;278:20171–8.PubMedCrossRef Feng ZP, Doering CJ, Winkfein RJ, Beedle AM, Spafford JD, Zamponi GW. Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. J Biol Chem. 2003;278:20171–8.PubMedCrossRef
16.
Zurück zum Zitat Bowersox SS, Singh T, Nadasdi L, Zukowska-Grojec Z, Valentino K, Hoffman BB. Cardiovascular effects of omega-conopeptides in conscious rats: mechanisms of action. J Cardiovasc Pharmacol. 1992;20:756–64.PubMed Bowersox SS, Singh T, Nadasdi L, Zukowska-Grojec Z, Valentino K, Hoffman BB. Cardiovascular effects of omega-conopeptides in conscious rats: mechanisms of action. J Cardiovasc Pharmacol. 1992;20:756–64.PubMed
17.
Zurück zum Zitat Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx. 2005;2:662–70.PubMedCrossRef Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx. 2005;2:662–70.PubMedCrossRef
18.
Zurück zum Zitat Winquist RJ, Pan JQ, Gribkoff VK. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem Pharmacol. 2005;70:489–99.PubMedCrossRef Winquist RJ, Pan JQ, Gribkoff VK. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem Pharmacol. 2005;70:489–99.PubMedCrossRef
19.
Zurück zum Zitat Priest BT, Swensen AM, McManus OB. Automated electrophysiology in drug discovery. Curr Pharm Des. 2007;13:2325–37.PubMedCrossRef Priest BT, Swensen AM, McManus OB. Automated electrophysiology in drug discovery. Curr Pharm Des. 2007;13:2325–37.PubMedCrossRef
20.
Zurück zum Zitat Dai G, Haedo RJ, Warren VA, Ratliff KS, Bugianesi RM, Rush A, et al. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev Technol. 2008;6:195–212.PubMedCrossRef Dai G, Haedo RJ, Warren VA, Ratliff KS, Bugianesi RM, Rush A, et al. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev Technol. 2008;6:195–212.PubMedCrossRef
21.
Zurück zum Zitat Lubin ML, Reitz TL, Todd MJ, Flores CM, Qin N, Xin H. A nonadherent cell-based HTS assay for N-type calcium channel using calcium 3 dye. Assay Drug Dev Technol. 2006;4:689–94.PubMedCrossRef Lubin ML, Reitz TL, Todd MJ, Flores CM, Qin N, Xin H. A nonadherent cell-based HTS assay for N-type calcium channel using calcium 3 dye. Assay Drug Dev Technol. 2006;4:689–94.PubMedCrossRef
22.
Zurück zum Zitat Benjamin ER, Pruthi F, Olanrewaju S, Shan S, Hanway D, Liu X, et al. Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR. Biochem Pharmacol. 2006;72:770–82.PubMedCrossRef Benjamin ER, Pruthi F, Olanrewaju S, Shan S, Hanway D, Liu X, et al. Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR. Biochem Pharmacol. 2006;72:770–82.PubMedCrossRef
23.
Zurück zum Zitat Lin Y, McDonough SI, Lipscombe D. Alternative splicing in the voltage-sensing region of N-type CaV2.2 channels modulates channel kinetics. J Neurophysiol. 2004;92:2820–30.PubMedCrossRef Lin Y, McDonough SI, Lipscombe D. Alternative splicing in the voltage-sensing region of N-type CaV2.2 channels modulates channel kinetics. J Neurophysiol. 2004;92:2820–30.PubMedCrossRef
24.
Zurück zum Zitat Pajouhesh H, Feng ZP, Ding Y, Zhang L, Pajouhesh H, Morrison JL, et al. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorg Med Chem Lett. 2010;20:1378–83.PubMedCrossRef Pajouhesh H, Feng ZP, Ding Y, Zhang L, Pajouhesh H, Morrison JL, et al. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorg Med Chem Lett. 2010;20:1378–83.PubMedCrossRef
25.
Zurück zum Zitat Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med. 2008;9:505–17.PubMedCrossRef Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med. 2008;9:505–17.PubMedCrossRef
26.
Zurück zum Zitat Snutch T, Feng Z, Doering C. A new class of N-type calcium channel blocker efficacious in animal models of chronic pain. Soc Neurosci Abstr. 2001; 27:465.1. Snutch T, Feng Z, Doering C. A new class of N-type calcium channel blocker efficacious in animal models of chronic pain. Soc Neurosci Abstr. 2001; 27:465.1.
27.
Zurück zum Zitat Margolskee RF, McHendry-Rinde B, Horn R. Panning transfected cells for electrophysiological studies. Biotechniques. 1993;15:906–11.PubMed Margolskee RF, McHendry-Rinde B, Horn R. Panning transfected cells for electrophysiological studies. Biotechniques. 1993;15:906–11.PubMed
28.
Zurück zum Zitat Bean BP. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci USA. 1984;81:6388–92.PubMedCrossRef Bean BP. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci USA. 1984;81:6388–92.PubMedCrossRef
29.
Zurück zum Zitat Xia M, Imredy JP, Koblan KS, Bennett P, Connolly TM. State-dependent inhibition of L-type calcium channels: cell-based assay in high-throughput format. Anal Biochem. 2004;327:74–81.PubMedCrossRef Xia M, Imredy JP, Koblan KS, Bennett P, Connolly TM. State-dependent inhibition of L-type calcium channels: cell-based assay in high-throughput format. Anal Biochem. 2004;327:74–81.PubMedCrossRef
30.
Zurück zum Zitat Belardetti F, Tringham E, Eduljee C, Jiang X, Dong H, Hendricson A, et al. A fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers. Assay Drug Dev Technol. 2009;7:266–80.PubMedCrossRef Belardetti F, Tringham E, Eduljee C, Jiang X, Dong H, Hendricson A, et al. A fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers. Assay Drug Dev Technol. 2009;7:266–80.PubMedCrossRef
31.
Zurück zum Zitat Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, et al. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55:81–93.PubMedCrossRef Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, et al. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55:81–93.PubMedCrossRef
Metadaten
Titel
Comparative analysis of inactivated-state block of N-type (Cav2.2) calcium channels
verfasst von
Timothy A. Vortherms
Andrew M. Swensen
Wende Niforatos
James T. Limberis
Torben R. Neelands
Richard S. Janis
Rama Thimmapaya
Diana L. Donnelly-Roberts
Marian T. Namovic
Di Zhang
C. Brent Putman
Ruth L. Martin
Carol S. Surowy
Michael F. Jarvis
Victoria E. Scott
Publikationsdatum
01.07.2011
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammation Research / Ausgabe 7/2011
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-011-0322-9

Weitere Artikel der Ausgabe 7/2011

Inflammation Research 7/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.